Abstract
Hyper-activation of DNA repair pathways can enable tumor cells to survive DNA damage. Therefore, targeting specific DNA repair pathways might prove efficacious for cancer therapy. The advent of personalized therapy necessitates novel biomarkers to assess tumor response to therapy. Biological indicators are vital in the field of cancer research and treatment. The focus of this review is on the DNA repair machinery as an emerging target for enhancement of therapy. Additionally, DNA damage and repair biomarkers for prognosis in different types of cancer will be discussed. The application of biomarkers to assess tumor response to therapy based on targeting DNA repair pathways can potentially improve patient quality of life and aid in treatment design.
Keywords: Biomarkers, cancer therapy, DNA damage, DNA repair, PARP inhibitor, personalized medicine, DNA lesions, genomic integrity, genome replication, transcription, apoptosis, necrosis, base excision repair, nucleotide excision repair, genomic instability
Current Molecular Medicine
Title:Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Volume: 12 Issue: 6
Author(s): S. Nowsheen, A. C. Whitley and E. S. Yang
Affiliation:
Keywords: Biomarkers, cancer therapy, DNA damage, DNA repair, PARP inhibitor, personalized medicine, DNA lesions, genomic integrity, genome replication, transcription, apoptosis, necrosis, base excision repair, nucleotide excision repair, genomic instability
Abstract: Hyper-activation of DNA repair pathways can enable tumor cells to survive DNA damage. Therefore, targeting specific DNA repair pathways might prove efficacious for cancer therapy. The advent of personalized therapy necessitates novel biomarkers to assess tumor response to therapy. Biological indicators are vital in the field of cancer research and treatment. The focus of this review is on the DNA repair machinery as an emerging target for enhancement of therapy. Additionally, DNA damage and repair biomarkers for prognosis in different types of cancer will be discussed. The application of biomarkers to assess tumor response to therapy based on targeting DNA repair pathways can potentially improve patient quality of life and aid in treatment design.
Export Options
About this article
Cite this article as:
Nowsheen S., C. Whitley A. and S. Yang E., Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy, Current Molecular Medicine 2012; 12 (6) . https://dx.doi.org/10.2174/156652412800792615
DOI https://dx.doi.org/10.2174/156652412800792615 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology Treatment of Choroidal Neovascularization in High Myopia
Current Drug Targets Arthropathy in Patients with CREST Variant Scleroderma
Current Rheumatology Reviews Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Treatment of Recurrent Epistaxis in HHT
Current Pharmaceutical Design Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Medical Treatment of Chronic Venous Insufficiency
Vascular Disease Prevention (Discontinued) Molecular Modeling of Sulfonylmorpholinopyrimidines as the Ataxia Telangiectasis Mutated and RAD3-related (ATR) Protein Kinase Inhibitors by Computational Explorations
Letters in Drug Design & Discovery Editorial [Hot Topic: Targeting Mast Cells and Basophils in Allergy and Beyond: Emerging Concepts (Executive Guest Editor: Petr Heneberg)]
Current Pharmaceutical Design Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets